Absstract of: WO2022193980A1

The present invention provides an antibody or an antigen-binding fragment thereof for novel coronavirus nucleocapsid protein, and an application thereof. The antibody is selected from any one of mAb6 antibody, mAb7 antibody, mAb8 antibody and mAb9 antibody; and the antibody is secreted by hybridoma cells having the accession numbers of CCTCC NO: C2020236, CCTCC NO: C2020237, CCTCC NO: C2020238 or CCTCC NO: C2020239. The presence of a novel coronavirus or an antigen thereof in an environmental sample and/or a biological sample can be detected by using the antibody. In addition, the present invention also provides a novel coronavirus detection kit prepared by using the antibody, capable of detecting the nucleocapsid protein in the early stage of infection, thereby providing a means to make the clinical detection of a novel coronavirus fast and precise.

Absstract of: WO2022197266A1

The present invention provides the beta-lactoglobulin protein and beta-lactoglobulin derived bioactive peptides from the whey fraction of goat milk and antiviral uses thereof, is preventive from infectious diseases and have effects of disease prevention and immune system by affecting on the entry gates of other types of coronaviruses [SARS CoV 2 besides SARS CoV and MERS]. Within the scope of the invention, ALPMHIR (SEQ ID NO:1), GLDIQK (SEQ ID NO:2), TPEVDK (SEQ ID NO:3), IPAVFK (SEQ ID NO:4), EALEK (SEQ ID NO:5) and IIAEK (SEQ ID NO:6) peptides are presented for use in the prevention and also potential treatment of infectious diseases, particularly COVID-19 (SARS-CoV-2).

Absstract of: WO2022198073A1

Provided are methods for modification of amino acid sequence and increasing levels of expression of ApoA-I Binding Protein to treat: a neuropathic pain, a CNS inflammation, an allodynia, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy, a neurodegeneration, including for example, a neurodegenerative disease or condition such as Alzheimer's disease, a hyperalgesia, primary headaches such as migraines and cluster headaches, glaucoma or other inflammatory diseases of the eye, lung inflammation, asthma, HIV infection, vascular inflammation, atherosclerosis and cardiovascular disease. Provided are methods comprising administering pharmaceutical compositions comprising a recombinantly modified APOA1BP polypeptide to treat a neuropathic pain, an allodynia, a hyperalgesia, a neurodegenerative disease, a primary headache such as a migraine, glaucoma, lung inflammation and asthma, acute respiratory distress syndrome (ARDS), sepsis, viral infection, including influenza, coronavirus (for example, COVID-19) or HIV infection, or its comorbidities, and/or vascular inflammation, atherosclerosis and cardiovascular disease.

Absstract of: WO2022197664A1

This disclosure relates to SARS-CoV-2 antibodies disclosed herein and specific binding fragments thereof, therapeutic and diagnostic uses, and compositions related thereto. In certain embodiments, this disclosure relates to antibodies disclosed herein and specific binding fragments thereof wherein the antibody or fragment specifically binds to an epitope expressed on a SARS-CoV-2 particle such as the spike protein or receptor binding domain. In certain embodiments, this disclosure relates to treating or preventing a SARS-CoV-2 or related coronavirus infection comprising administering an effective amount of an antibody disclosed herein or specific binding fragments thereof to a subject in need thereof.

Absstract of: WO2022197840A1

The present invention includes methods and compositions useful for treating or preventing a coronavirus infection in a subject. In certain embodiments the treatment comprises adenoviral-based vaccines against SARS-CoV-2 viral proteins.

Absstract of: WO2022197626A1

The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of cidofovir and a second antiviral agent. Also provided are formulations and methods of delivering the formulations to an individual.

Absstract of: WO2022197625A1

The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of peramivir and a second antiviral agent. Also provided are formulations and methods of delivering the formulations to an individual.

Absstract of: WO2022197635A1

Provided herein, in some embodiments, are rapid diagnostic tests to detect one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens). In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. Further embodiments provide methods of detecting genetic abnormalities. Diagnostic tests comprising a sample-collecting component, one or more reagents (e.g., lysis reagents, nucleic acid amplification reagents), and a detection component (e.g., a component comprising a lateral flow assay strip) are provided.

Absstract of: WO2022197627A1

The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of nevirapine and an effective amount of valacyclovir and/or nevirapine. Also provided are formulations and methods of delivering the formulations to an individual.

Absstract of: WO2022195351A1

The invention describes vaccines useful for the prevention of COVID-19, wherein recombinant antigens of non-glycosylated domains in the S-RBD region encoded in the SARS-CoV-2 virus genome of both the original Wuhan virus strain and the B.1.1.7 (UK) and B.1.351 (South African) virus strain variants were designed and expressed. The purified antigens of the invention were able to induce the production of polyclonal antibodies in animals, as well as a strong immune response, even by means of nasal and/or intranasal administration. Additionally, IgG antibodies that recognise said antigens were detected in sera from recovered COVID-19 patients. The invention highlights the usefulness of the antigens based on the non-N-glycosylated region of the RBD of SARS-CoV-2 for the development of monovalent and/or polyvalent vaccines effective against COVID-19, for the diagnosis of said illness, and for the prevention and immunotherapy thereof by means of the production and use of monovalent and/or polyvalent anti-COVID-19 hyperimmune plasmas and/or sera.

Absstract of: AU2021231743A1

Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a bacterium, fungus, and/or virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed.

Absstract of: AU2021228008A1

Use of a compound represented by formula (I) or pharmaceutically acceptable salts thereof in the preparation of drugs for preventing or treating coronavirus infectious diseases. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in negative conversion ratio of viral nucleic acid test, negative conversion course, and cure and hospital discharge time.

Absstract of: AU2021226592A1

The invention relates in various aspects to a recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, methods for producing such viruses and the use of such viruses. The recombinant poxviruses are well suited, among others, as protective virus vaccines against SARS-CoV-2 virus.

Absstract of: AU2021221127A1

SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.

Absstract of: AU2021224298A1

Compositions, assays, methods, diagnostic methods, kits, and diagnostic kits are disclosed for the specific and differential detection of SARS-CoV-2 and/or other viruses from samples, including veterinary samples, clinical samples, food samples, forensic sample, environmental samples (e.g., obtained from soil, garbage, sewage, air, water, food processing and manufacturing surfaces, or likewise), or biological sample obtained from a human or non-human animal.

Absstract of: WO2022197209A1

Group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing expression vector based on strain human adenovirus serotype 26 or human adenovirus serotype 5, in which E1 and E3 regions are deleted, with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or simian adenovirus serotype 25, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 or contains only component 2 for for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.

Absstract of: WO2022193553A1

Disclosed in the present invention are an influenza virus vector-based novel coronavirus vaccine and a preparation method therefor. The vaccine can efficiently express two antigens, i.e., an HA antigen of the vaccine and an exogenous SC2R1 antigen, such that the vaccine can induce immune response of the two antigens to achieve the purpose of preventing influenza viruses and novel coronaviruses at the same time, and reduce the influences of two infectious diseases, i.e., influenza and novel coronaviruses, on the social economy, etc. Moreover, an influenza vaccine can be prepared and produced on a large scale on the basis of existing mature influenza platform technologies, and the influenza vaccine has a long use history and good safety.

Absstract of: WO2022197853A1

The disclosure provides example devices and methods for making and using the devices for rapid testing for the SARS-CoV-2 virus. The example device includes (a) a substrate coupled to a metal oxide layer, (b) a graphene layer coupled to the metal oxide layer, (c) a chemical or biochemical linker functionalized with the graphene layer, and (d) a plurality of SARS-CoV-2 receptors that are bound to the graphene layer via the chemical or biochemical linker, wherein the plurality of SARS-CoV-2 receptors comprise SARS-CoV-2 spike antibodies or SARS-CoV-2 spike proteins, where the graphene layer is configured to have a first phononic energy, when the plurality of SARS-CoV-2 receptors are unattached to target molecules, and a second phononic energy, when the plurality of SARS-CoV-2 receptors are attached to target molecules.

Absstract of: WO2022197624A1

The disclosure describes coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.

Absstract of: WO2022195558A1

Compositions and methods for treating a SARS-CoV-2 infection are provided. The disclosed compositions and methods are based on an interaction pathways and inhibition of serine 206 phosphorylation of the Nucleocapsid (N) protein of SARS-CoV-2. The compositions include one of more compounds capable of inhibition of phosphorylation of the Nucleocapsid serine 206. The amount of one or more compounds can be effective to, for example, reduce viral replication, reduce one or more symptoms of a disease, disorder, or illness associated with virus, or a combination thereof. Method for identifying a subject as having an elevated risk of developing one or more symptoms associated with severe COVID-19 are also provided.

Absstract of: WO2022195455A1

A method to produce immunoglobulin preparations against viral infection in humans spreading via respiratory route is provided. The method comprises the steps of immunizing dairy cows during a third trimester of at least a first gestation period with antigen proteins derived from at least one virus strain, collecting hyperimmune bovine colostrum comprising immunoglobulins effective against the antigen protein of various strains of the virus, preparing whey from the colostrum, isolating the immunoglobulin molecules from the whey, and preparing an immunoglobulin preparation for use as an intranasal treatment. One aspect of the invention is to produce SARS-CoV-2 spike protein specific hyperimmune bovine colostrum comprising a high concentration of anti-SARS-CoV-2 antibodies. An intranasal delivery system for diminishing risk of SARS-CoV-2 infections in humans is provided.

Absstract of: WO2022194756A2

Methods for the rapid detection of the presence of variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that contain mutations in the Spike (S) protein gene in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2 variants containing S gene mutations and kits are provided that are designed for the detection of SARS-CoV-2 variants containing S gene mutations.

Absstract of: WO2022195096A1

The invention relates to a peptide comprising or consisting of an amino acid sequence FIEDLLFNKVT (SEQ ID NO 1) or a sequence of at least 80%, preferably at least 90%, sequence identity thereto. In embodiments, the peptide is of up to 25 amino acids, or 15-25 amino acids. The invention further relates to a nucleic acid molecule encoding the peptide of the invention, a solid phase comprising the peptide of the invention, an in vitro method for assessing the risk of a subject in developing a severe acute respiratory syndrome (SARS) or other adverse event or severe medical condition associated with SARS-CoV infection, comprising use of the peptide of the invention, the peptide of the invention for use in an immunogenic composition, such as a vaccine, a kit for performing the method, and a method for assessing the functional avidity of T cells for one or more antigens, employing the peptide of the invention.

Absstract of: US2022296701A1

A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 μg of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.

Absstract of: EP4059493A1

Pharmaceutical composition comprises of Chlorophyllin or salts thereof and its utilities including method of treatment, enabling the absorption of Copper-isochlorin e4 into human blood that results in an increase in lymphocyte count and decrease in the abundance of hematopoietic stem and progenitor cells (HPSCs) in human blood. The invention is directed to the treatment of conditions including corona-virus infection, immunosuppression, leucopenia and lymphopenia. The composition disclosed in the invention is thus useful for the treatment of corona virus disease caused by SARS-CoV-2 infection by decreasing viral infection, reducing cytokine storm and pro-inflammatory chemokines, reducing epithelial-cell oxidative-stress in the lungs and increasing the production of leukocytes.